Clinical trial
Radiolabeled Monoclonal Antibody Therapy and Etoposide Followed by Peripheral…
NCT00006040 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00006040 |
|---|---|
| Title | Radiolabeled Monoclonal Antibody Therapy and Etoposide Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Myelodysplastic Syndrome or Refractory Leukemia |
| Official title | Phase I Study of Yttrium-90 Labeled HuM195 Combined With Etoposide as a Conditioning Regimen for Autologous Stem Cell Transplantation in Patients With Advanced Myelodysplastic Syndrome and Refractory Leukemia |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms |
| Intervention type | Biological, Drug, Procedure, Radiation |
| Interventions | filgrastim, etoposide, autologous bone marrow transplantation, peripheral blood stem cell transplantation, yttrium Y 90 monoclonal antibody M195 |
| Start date | Apr 1, 2000 |
| Primary completion | Nov 1, 2003 |
| Completion | Nov 1, 2003 |
| First posted | Jan 27, 2003 |
| Last update posted | Jun 19, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: